Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M52.2Revenue (TTM) $M5.4Net Margin (%)0.6Altman Z-Score4.7
Enterprise Value $M54.5EPS (TTM) $--Operating Margin %2.5Piotroski F-Score3
P/E(ttm)--Beneish M-Score0.8Pre-tax Margin (%)0.6Higher ROA y-yY
Price/Book12.610-y EBITDA Growth Rate %--Quick Ratio1.2Cash flow > EarningsN
Price/Sales10.05-y EBITDA Growth Rate %--Current Ratio1.2Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)0.4Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)0.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M63.6ROIC % (ttm)3.1Gross Margin Increase y-yN

Gurus Latest Trades with IGXT

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

IGXT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


IGXT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Boudreau BernardDirector 2016-01-22Buy65,000$0.4967.35view
Bechard Robert J.VP Corporate Development 2016-01-22Buy10,000$0.564view
Godin AndreEVP + CFO 2016-01-20Buy20,000$0.4105view
Godin AndreEVP & CFO 2015-12-30Buy9,500$0.5257.69view
Godin AndreEVP + CFO 2015-12-23Buy15,350$0.5160.78view
Godin AndreEVP + CFO 2015-12-22Buy19,650$0.564view
Zerbe IngridCorporate Secretary 2015-08-25Sell163,100$0.564view
Zerbe Horst GCEO 2015-08-25Sell36,900$0.564view
Zerbe IngridCorporate Secretary 2015-04-20Sell66,900$0.6624.24view
Zerbe Horst GCEO 2015-04-17Sell60,000$0.6624.24view

Press Releases about IGXT :

Quarterly/Annual Reports about IGXT:

News about IGXT:

Articles On GuruFocus.com
No related article found.

More From Other Websites
IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative... Aug 22 2016
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Aug 22 2016
IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative... Aug 22 2016
INTELGENX TECHNOLOGIES CORP. Financials Aug 19 2016
IntelGenx reports 2Q loss Aug 11 2016
IntelGenx reports 2Q loss Aug 11 2016
IntelGenx Reports Second Quarter 2016 Financial Results and Appointment of New Director Aug 11 2016
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Other... Aug 11 2016
IntelGenx Reports Second Quarter 2016 Financial Results and Appointment of New Director Aug 11 2016
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Aug 08 2016
IntelGenx Announces Sale of Forfivo XL(R) Royalty for $6 Million Aug 05 2016
IntelGenx Announces Sale of Forfivo XL(R) Royalty for $6 Million Aug 05 2016
IntelGenx to Report Second Quarter 2016 Financial Results on August 11, 2016 Aug 02 2016
IntelGenx to Report Second Quarter 2016 Financial Results on August 11, 2016 Aug 02 2016
IntelGenx to Initiate Phase 1 Trial of Montelukast Jul 13 2016
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Jul 13 2016
IntelGenx to Initiate Phase 1 Trial of Montelukast Jul 13 2016
IntelGenx Announces Notice of Appeal for Buprenorphine/Naloxone Sublingual Film Product for the... Jul 11 2016
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Jul 11 2016
IntelGenx Announces Notice of Appeal for Buprenorphine/Naloxone Sublingual Film Product for the... Jul 11 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)